WO2000051593A3 - Oral drug delivery system - Google Patents

Oral drug delivery system

Info

Publication number
WO2000051593A3
WO2000051593A3 PCT/GB2000/000664 GB0000664W WO0051593A3 WO 2000051593 A3 WO2000051593 A3 WO 2000051593A3 GB 0000664 W GB0000664 W GB 0000664W WO 0051593 A3 WO0051593 A3 WO 0051593A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
oral drug
delivery system
oral
protein
Prior art date
Application number
PCT/GB2000/000664
Other languages
French (fr)
Other versions
WO2000051593A2 (en
Inventor
Peter Watts
Ian Lafferty
Original Assignee
West Pharm Serv Drug Res Ltd
Peter Watts
Ian Lafferty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd, Peter Watts, Ian Lafferty filed Critical West Pharm Serv Drug Res Ltd
Priority to EP00906469A priority Critical patent/EP1156793A2/en
Priority to AU28133/00A priority patent/AU2813300A/en
Priority to JP2000602061A priority patent/JP2002538112A/en
Priority to CA002363592A priority patent/CA2363592A1/en
Publication of WO2000051593A2 publication Critical patent/WO2000051593A2/en
Publication of WO2000051593A3 publication Critical patent/WO2000051593A3/en
Priority to NO20014035A priority patent/NO20014035L/en
Priority to US09/943,691 priority patent/US20020098198A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Abstract

An oral drug delivery composition that dissolves rapidly in the mouth, which comprises on a solid foam formed from a protein.
PCT/GB2000/000664 1999-03-02 2000-02-24 Oral drug delivery system WO2000051593A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00906469A EP1156793A2 (en) 1999-03-02 2000-02-24 Oral drug delivery system
AU28133/00A AU2813300A (en) 1999-03-02 2000-02-24 Oral drug delivery system
JP2000602061A JP2002538112A (en) 1999-03-02 2000-02-24 Oral drug delivery system
CA002363592A CA2363592A1 (en) 1999-03-02 2000-02-24 Oral drug delivery system
NO20014035A NO20014035L (en) 1999-03-02 2001-08-20 Oral drug administration system
US09/943,691 US20020098198A1 (en) 1999-03-02 2001-08-31 Oral drug delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9904629.4A GB9904629D0 (en) 1999-03-02 1999-03-02 Oral drug delivery system
GB9904629.4 1999-03-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/943,691 Continuation US20020098198A1 (en) 1999-03-02 2001-08-31 Oral drug delivery system

Publications (2)

Publication Number Publication Date
WO2000051593A2 WO2000051593A2 (en) 2000-09-08
WO2000051593A3 true WO2000051593A3 (en) 2000-12-28

Family

ID=10848692

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000664 WO2000051593A2 (en) 1999-03-02 2000-02-24 Oral drug delivery system

Country Status (10)

Country Link
US (1) US20020098198A1 (en)
EP (1) EP1156793A2 (en)
JP (1) JP2002538112A (en)
AU (1) AU2813300A (en)
CA (1) CA2363592A1 (en)
GB (1) GB9904629D0 (en)
NO (1) NO20014035L (en)
NZ (1) NZ513700A (en)
WO (1) WO2000051593A2 (en)
ZA (1) ZA200107123B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9904911D0 (en) * 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6090401A (en) * 1999-03-31 2000-07-18 Mcneil-Ppc, Inc. Stable foam composition
HU229550B1 (en) * 2000-06-27 2014-01-28 Hoffmann La Roche Method for preparing compositions
DE10032456A1 (en) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Rapidly disintegrating dosage form for the release of active substances in the mouth or in the body cavities
FR2824477B1 (en) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques ENVELOPED GRANULES BASED ON INHIBITOR OF THE ANFIOTENSIN CONVERTING ENZYME, PROCESS FOR THEIR PREPARATION AND ORODISPERSIBLE TABLETS CONTAINING COATED GRANULES
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
JP4902103B2 (en) * 2002-04-11 2012-03-21 メディミューン・エルエルシー Preservation of bioactive materials in lyophilized foam
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
MXPA05005528A (en) 2002-11-26 2006-04-05 Alk Abello As Pharmaceutical allergen product.
US20040151756A1 (en) * 2003-02-04 2004-08-05 Richards Anthony P. Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
DK1804764T3 (en) * 2004-10-28 2008-09-29 Pantec Ag Preparation of a rapidly decaying solid composition from a solid powder and a freeze-drying step
US20060147516A1 (en) * 2005-01-06 2006-07-06 Cima Labs Inc. Taste masking system for alprazolam
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
JP2018501814A (en) 2014-11-11 2018-01-25 クララ フーズ カンパニー Methods and compositions for egg white protein production
EP3452023A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP2022539879A (en) 2019-07-11 2022-09-13 クララ フーズ カンパニー Protein composition and consumable products thereof
US10927360B1 (en) 2019-08-07 2021-02-23 Clara Foods Co. Compositions comprising digestive enzymes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295865A2 (en) * 1987-06-15 1988-12-21 Sbp, Inc. Comestibles containing parenchymal cell cellulose
EP0362655A1 (en) * 1988-10-01 1990-04-11 CASSELLA Aktiengesellschaft Foamable medicinal mixture
WO1991009591A1 (en) * 1989-12-22 1991-07-11 Mediventures, Inc. Preparation of pharmaceutical and other matrix systems by solid-state dissolution
EP0450141A1 (en) * 1989-08-14 1991-10-09 Janssen Pharmaceutica Inc. Carrier material for administration of drugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295865A2 (en) * 1987-06-15 1988-12-21 Sbp, Inc. Comestibles containing parenchymal cell cellulose
EP0362655A1 (en) * 1988-10-01 1990-04-11 CASSELLA Aktiengesellschaft Foamable medicinal mixture
EP0450141A1 (en) * 1989-08-14 1991-10-09 Janssen Pharmaceutica Inc. Carrier material for administration of drugs
WO1991009591A1 (en) * 1989-12-22 1991-07-11 Mediventures, Inc. Preparation of pharmaceutical and other matrix systems by solid-state dissolution

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy

Also Published As

Publication number Publication date
WO2000051593A2 (en) 2000-09-08
NO20014035D0 (en) 2001-08-20
NZ513700A (en) 2001-09-28
GB9904629D0 (en) 1999-04-21
JP2002538112A (en) 2002-11-12
US20020098198A1 (en) 2002-07-25
NO20014035L (en) 2001-10-22
CA2363592A1 (en) 2000-09-08
AU2813300A (en) 2000-09-21
EP1156793A2 (en) 2001-11-28
ZA200107123B (en) 2003-02-26

Similar Documents

Publication Publication Date Title
WO2000051593A3 (en) Oral drug delivery system
HK1053217A1 (en) Short message delivery system.
HK1048427A1 (en) Drug delivery device.
MXPA01010676A (en) Pharmaceutical composition.
HK1036230A1 (en) Drug delivery devices.
WO2002010192A3 (en) Somatostatin analogues
EP1025858A4 (en) Medicinal compositions with relieved bitterness, etc.
MXPA03002874A (en) Pesticide delivery system.
MXPA03007215A (en) Pharmaceutical formulations.
MXPA03005044A (en) Reversible gelling system for ocular drug delivery.
WO2003011226A3 (en) Products and drug delivery vehicles
ZA200101012B (en) Pharmaceutical combinations.
ZA200005134B (en) Solid, quick dissolving cetirizine formulations.
ZA200001010B (en) Microdisperse drug delivery systems.
ZA200401217B (en) Zero order controlled drug delivery system.
ZA200203707B (en) Pharmaceutical combinations.
AU2001244713A1 (en) Transporters and drug delivery system by using the same
ZA200000857B (en) Pharmaceutical composition.
ZA200203390B (en) Vitamin D analogues.
ZA974270B (en) Pharmaceutical compositions based on diclofenac.
AU2001258443A1 (en) Drug delivery device, especially for the delivery of gestodene
HK1040488A1 (en) Pharmaceutical formulations.
HK1051003A1 (en) Ciclesonide-containing aqueous pharmaceutical composition.
ZA200409726B (en) Monocompartment osmotic controlled drug delivery system.
ZA200110454B (en) Pharmaceutical complex.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000906469

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 28133/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 513700

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2363592

Country of ref document: CA

Ref country code: CA

Ref document number: 2363592

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 602061

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09943691

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000906469

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000906469

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)